Southern Queensland Centre of Excellence in Aboriginal and Torres Strait Islander Primary Health Care, Brisbane, Australia.
School of Public Health, The University of Queensland, Brisbane, Australia.
Drug Alcohol Rev. 2018 Jan;37(1):87-96. doi: 10.1111/dar.12549. Epub 2017 May 10.
Indigenous Australians experience a significant gap in life expectancy compared with non-Indigenous Australians. Indigenous communities have high-smoking prevalence and low engagement with cessation therapies. This qualitative research, conducted in an urban Australian Indigenous community, explored smokers' views on smoking, quitting and engagement with current nicotine replacement therapies. Opinions on acceptability of tobacco harm reduction were sought. We explored the acceptability of novel nicotine products, that is, new or unfamiliar products, including non-therapeutic options, such as e-cigarettes.
Focus groups and individual interviews with adult Indigenous daily smokers (n = 27) were used. Current and novel nicotine products were displayed and demonstrated. Discussions were audio-recorded, transcribed and analysed thematically.
Participants expressed interest in trying existing and novel nicotine products. Short-to-medium term use of nicotine replacement therapy for quitting was generally acceptable; views on long-term use were mixed. Interest in use of tobacco substitutes depended on their perceived effectiveness, providing a 'kick' and 'relieving stress'. Desirable qualities for tobacco substitutes were identified with gender differences and product preferences noted. The unpleasant taste of existing products is a barrier to both short-term and long-term use.
We found substantial interest in trying some existing and novel nicotine products, mostly for short-term use. A number of attributes were identified that would make nicotine products potentially acceptable as a long-term substitute.
Some participants were interested in long-term substitution if acceptable products were available. Improvements in current products and access to novel products are needed if tobacco harm reduction is to be acceptable. [Yuke K, Ford P, Foley W, Mutch A, Fitzgerald L, Gartner C. Australian urban Indigenous smokers' perspectives on nicotine products and tobacco harm reduction. Drug Alcohol Rev 2018;37:87-96].
与非土著澳大利亚人相比，澳大利亚土著居民的预期寿命存在显著差距。土著社区吸烟率高，戒烟治疗参与度低。本项在澳大利亚一个城市土著社区进行的定性研究，探讨了吸烟者对吸烟、戒烟以及目前尼古丁替代疗法的看法，同时还探讨了他们对减少烟草危害的可接受性的看法。我们还探讨了新型尼古丁产品的可接受性，即新的或不熟悉的产品，包括非治疗性选择，例如电子烟。
采用焦点小组和个人访谈的方式，对成年土著吸烟者（n = 27）进行访谈。展示和演示了现有的和新型尼古丁产品。对讨论进行了录音、转录和主题分析。
参与者表示有兴趣尝试现有的和新型尼古丁产品。短期至中期使用尼古丁替代疗法戒烟通常是可以接受的；长期使用的看法则存在分歧。对使用烟草替代品的兴趣取决于其预期效果，即提供“刺激”和“缓解压力”。确定了烟草替代品的理想品质，同时注意到了性别差异和产品偏好。现有产品的不良味道是短期和长期使用的障碍。
我们发现，大多数参与者对尝试现有的和新型尼古丁产品有很大的兴趣，主要是短期使用。确定了一些潜在的属性，这些属性可以使尼古丁产品作为长期替代品被接受。
如果有合适的产品，一些参与者对长期替代有兴趣。如果要接受减少烟草危害，需要改进现有产品并获得新型产品。
